Secukinumab in multi-failure psoriatic patients: the last hope?-Reference-Cited by-同舟云学术

Secukinumab in multi-failure psoriatic patients: the last hope?

Published:2018-01-23 Issue:6 Volume:29 Page:583-585
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Magnano M.¹,Loi C.¹,Patrizi A.¹,Sgubbi P.¹,Balestri R.²,Rech G.²,Tasin L²,Girardelli C. R.²,Conti A.³,Odorici G.³,Campanati A.⁴,Offidani A. M.⁴,Bardazzi F.¹

Affiliation:

1. Department of Specialized, Diagnostic and Experimental Medicine University of Bologna, Italy;

2. Dermatology Division, Multizonale Santa Chiara Hospital, Trento, Italy;

3. Dermatology Unit, United Hospital of Ancona Polytechnic Marche University, Ancona, Italy;

4. Psoriasis Outpatient Clinic of the Polyclinic University Hospital, Modena, Italy

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2018.1427206

Reference5 articles.

1. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC

2. Secukinumab – first in class interleukin-17A inhibitor for the treatment of psoriasis

3. Switching biologics in the treatment of psoriatic arthritis

4. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition

5. Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi‐failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort;International Journal of Dermatology;2024-01-05

2. Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population;British Journal of Dermatology;2022-05-24

3. Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study;Dermatologic Therapy;2022-04-13

4. Increasing the dose of secukinumab in suboptimal responders: a possible therapeutic strategy;Italian Journal of Dermatology and Venereology;2022-04

5. Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching;Pharmaceuticals;2022-01-14